An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: An immunoproteomics investigation

In the current study, we have used an immunoproteomics approach to identify proteins that commonly elicit a humoral response in patients with infiltrating ductal carcinomas of the breast. Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2011-09, Vol.44 (13), p.1097-1104
Main Authors: Hamrita, Bechr, Nasr, Hela Ben, Hammann, Philippe, Kuhn, Lauriane, Guillier, Christelle-Lemaitre, Chaieb, Anouar, Khairi, Hedi, Chahed, Karim
Format: Article
Language:English
Subjects:
Antibodies, Neoplasm - blood
Antigens, Neoplasm - analysis
Autoantibody
Biological and medical sciences
Carcinoma, Ductal, Breast - diagnosis
Carcinoma, Ductal, Breast - immunology
Case-Control Studies
Cell Line, Tumor
Elongation factor Tu
Female
Gynecology. Andrology. Obstetrics
Humans
Immunity, Humoral
Immunoglobulin G - blood
Immunoproteomics
Infiltrating ductal breast carcinomas
Life Sciences
Mammary gland diseases
Medical sciences
Peptide Elongation Factor Tu - blood
Peptide Elongation Factor Tu - immunology
Proteomics - methods
Serologic Tests - methods
SERPA
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the current study, we have used an immunoproteomics approach to identify proteins that commonly elicit a humoral response in patients with infiltrating ductal carcinomas of the breast. Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened for the presence of IgG antibodies to MCF-7 cell line proteins using a serological proteomics-based approach. An immunoreactive protein detected in sera from 21 of 40 patients was isolated and subsequently identified as elongation factor-Tu. The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that induce a humoral immune response in cancer patients. From our findings, the immunoreactive EF-Tu protein and/or the related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2011.06.005